Cargando…

Combination of Liposomal CpG Oligodeoxynucleotide 2006 and Miltefosine Induces Strong Cell-Mediated Immunity during Experimental Visceral Leishmaniasis

Immuno-modulators in combination with antileishmanial drug miltefosine is a better therapeutic approach for treatment of Visceral Leishmaniasis (VL) as it not only reduces the dose of miltefosine but also shortens the treatment regimen. However, immunological mechanisms behind the perceived benefits...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shivahare, Rahul, Vishwakarma, Preeti, Parmar, Naveen, Yadav, Pawan Kumar, Haq, Wahajul, Srivastava, Mrigank, Gupta, Suman, Kar, Susanta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986403/ https://www.ncbi.nlm.nih.gov/pubmed/24732039 http://dx.doi.org/10.1371/journal.pone.0094596

Ejemplares similares

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
por: Patra, Pradyumna, et al.
Publicado: (2012)

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
por: Srivastava, Saumya, et al.
Publicado: (2017)

Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
por: dos Santos Nogueira, Fabio, et al.
Publicado: (2019)

Clinical and Laboratory Response of Domiciled Dogs with Visceral Leishmaniasis Treated with Miltefosine and Allopurinol
por: Vaz, Talita Pereira, et al.
Publicado: (2023)

Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting Leishmania donovani Strain
por: Rai, Keshav, et al.
Publicado: (2013)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
por: Carnielli, Juliana B.T., et al.
Publicado: (2018)

Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis
por: Melcon-Fernandez, Estela, et al.
Publicado: (2023)

CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015)

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
por: Bhandari, Vasundhra, et al.
Publicado: (2012)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil
por: Carnielli, Juliana B. T., et al.
Publicado: (2019)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B
por: McQuarrie, Shauna, et al.
Publicado: (2015)

Interferon-α/β receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006
por: Kato, Atsushi, et al.
Publicado: (2003)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

A case of canine visceral leishmaniasis of unknown origin in Curitiba (state of Paraná, Brazil) treated successfully with miltefosine
por: Gonçalves, Gustavo, et al.
Publicado: (2023)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

Neonate Intestinal Immune Response to CpG Oligodeoxynucleotide Stimulation
por: Lacroix-Lamandé, Sonia, et al.
Publicado: (2009)

Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin A Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes
por: Tada, Rui, et al.
Publicado: (2022)

Influence of the Charge Ratio of Guanine-Quadruplex Structure-Based CpG Oligodeoxynucleotides and Cationic DOTAP Liposomes on Cytokine Induction Profiles
por: Le, Nguyen Bui Thao, et al.
Publicado: (2023)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

N-Acetyl-l-Leucine-Polyethyleneimine-Mediated Delivery of CpG Oligodeoxynucleotides 2006 Inhibits RAW264.7 Cell Osteoclastogenesis
por: Wang, Huining, et al.
Publicado: (2020)

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
por: Hanagata, Nobutaka
Publicado: (2012)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis
por: Romanelli, Maiara Maria, et al.
Publicado: (2019)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2015)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k17721kojbcockbm9k6e8f75th